Tissue-targeted mRNA-LNP OSK delivery with NAD+ boosting enables repeatable, safe partial reprogramming for multi-organ rejuvenation

Hypothesis

Cyclic administration of OSK mRNA packaged in lipid nanoparticles functionalized with tissue‑specific ligands (galactose for hepatocytes, transferrin for neurons, and peptide‑based ligands for muscle) together with intermittent NAD+ precursor supplementation will achieve sustained epigenetic rejuvenation across liver, brain, and skeletal muscle without inducing tumorigenic transformation, outperforming AAV‑mediated OSK in terms of repeatability and safety.

Rationale

Partial reprogramming resets epigenetic age by transient OSK expression, yet delivery remains the bottleneck. AAV provides long‑term expression but poses immunogenicity and re‑dosing limits, while naked mRNA‑LNP offers vaccine‑like repeatability but suffers from poor tissue selectivity. Recent work shows that metabolic cofactors such as B12 enhance reprogramming efficiency [8]; NAD+ boosters similarly improve sirtuin activity and chromatin remodeling, lowering the OSK exposure needed for rejuvenation. Ligand‑decorated LNPs have demonstrated organ‑specific mRNA delivery in vaccine and therapeutic contexts, suggesting a feasible path to target reprogramming factors where they are most needed while sparing off‑target tissues.

Predictions

If the hypothesis is correct, aged mice receiving the proposed regimen will show:

• A significant reduction in epigenetic age (measured by Horvath‑style clocks) in liver, hippocampus, and gastrocnemius after four cycles, comparable to or exceeding the 109% lifespan extension seen with AAV‑OSK [1].
• Improved functional assays: hepatic glucose tolerance, neuronal synaptic plasticity, and muscle grip strength.
• No increase in tumorigenesis or teratoma formation over a 12‑month observation period, confirmed by histopathology and karyotyping.
• Lower circulating anti‑OSK antibody titers compared with AAV‑OSK, indicating reduced immune memory.

Experimental Design

1. Formulation: Produce OSK‑mRNA LNPs conjugated with galactose, transferrin, or a muscle‑homing peptide (e.g., CKGGRAKDC). Include a control LNP with no ligand.
2. Dosing schedule: Administer LNPs intravenously every two weeks for three doses per cycle, with four cycles total. Concurrently give nicotinamide riboside (NR) at 400 mg/kg diet on alternate days to elevate NAD+.
3. Readouts:
   • Epigenetic clocks from isolated tissue DNA at baseline, mid‑study, and endpoint.
   • Functional assays: serum ALT/AST, Morris water maze, rotarod.
   • Safety: MRI for tumor incidence, flow cytometry for pluripotency markers (OCT4, SSEA1) in non‑target tissues, serum cytokines.
4. Statistical analysis: Use two‑way ANOVA with factors treatment and tissue, followed by Tukey post‑hoc; significance set at p<0.05.

Potential Outcomes

• Success: Demonstrated multi‑tissue rejuvenation with safety profile matching or exceeding AAV‑OSK, validating LNP‑ligand plus NAD+ as a clinically translatable platform.
• Partial success: Rejuvenation observed in liver but not brain/muscle, indicating need for further ligand optimization or dosing adjustment.
• Failure: No epigenetic improvement or emergence of off‑target proliferation, falsifying the hypothesis and suggesting that mRNA‑LNP cannot achieve sufficient nuclear OSK levels or that NAD+ boosting does not lower the threshold for safe reprogramming.

This approach directly tests whether combining metabolic enhancement with precision delivery can overcome the current delivery bottleneck and unlock repeatable, systemic partial reprogramming for aging intervention.